I agree MM, it's stupidly cheap for a company that has built up so much IP in the drugs Albendazole and MPL and the progress being made by Epichem. But markets are like that, fickle, and past disappointments hang around like a bad smell. What this market is looking is for something to break it out of that emotional rut. A clear breakthrough in the palatability issues and re-commencement of ph 2 would probably do that as would continued improvement in finances from Epichem.
I agree MM, it's stupidly cheap for a company that has built up...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |